Literature DB >> 29596544

Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.

Shaodong Hong1,2,3, Fangfang Gao1,2,3, Sha Fu4, Yan Wang5, Wenfeng Fang1,2,3, Yan Huang1,2,3, Li Zhang1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29596544      PMCID： PMC5885210          DOI： 10.1001/jamaoncol.2018.0049

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

2.  Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Authors:  Chee Khoon Lee; Yi-Long Wu; Pei Ni Ding; Sarah J Lord; Akira Inoue; Caicun Zhou; Tetsuya Mitsudomi; Rafael Rosell; Nick Pavlakis; Matthew Links; Val Gebski; Richard J Gralla; James Chih-Hsin Yang
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

3.  Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.

Authors:  June-Koo Lee; Seokyung Hahn; Dong-Wan Kim; Koung Jin Suh; Bhumsuk Keam; Tae Min Kim; Se-Hoon Lee; Dae Seog Heo
Journal:  JAMA       Date:  2014-04-09       Impact factor: 56.272

4.  Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.

Authors:  Song Xu; Feng Lou; Yi Wu; Da-Qiang Sun; Jing-Bo Zhang; Wei Chen; Hua Ye; Jing-Hao Liu; Sen Wei; Ming-Yu Zhao; Wen-Jun Wu; Xue-Xia Su; Rong Shi; Lindsey Jones; Xue F Huang; Si-Yi Chen; Jun Chen
Journal:  Cancer Lett       Date:  2015-11-12       Impact factor: 8.679

5.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

6.  Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Authors:  Collin M Blakely; Thomas B K Watkins; Wei Wu; Beatrice Gini; Jacob J Chabon; Caroline E McCoach; Nicholas McGranahan; Gareth A Wilson; Nicolai J Birkbak; Victor R Olivas; Julia Rotow; Ashley Maynard; Victoria Wang; Matthew A Gubens; Kimberly C Banks; Richard B Lanman; Aleah F Caulin; John St John; Anibal R Cordero; Petros Giannikopoulos; Andrew D Simmons; Philip C Mack; David R Gandara; Hatim Husain; Robert C Doebele; Jonathan W Riess; Maximilian Diehn; Charles Swanton; Trever G Bivona
Journal:  Nat Genet       Date:  2017-11-06       Impact factor: 38.330
  6 in total
  59 in total

1.  Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.

Authors:  Li-Li Deng; Ge Gao; Hong-Bin Deng; Feng Wang; Zhi-Hui Wang; Yu Yang
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-28       Impact factor: 4.553

2.  Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.

Authors:  Xiaohong Han; Rongrong Luo; Lin Wang; Lei Zhang; Tao Wang; Yan Zhao; Shanshan Xiao; Nan Qiao; Chi Xu; Lieming Ding; Zhishang Zhang; Yuankai Shi
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

3.  Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.

Authors:  Yuan Tang; Nanying Che; Yang Yu; Yun Gao; Huaiyin Shi; Qin Feng; Bing Wei; Liheng Ma; Min Gao; Jie Ma; Dongmei Lin
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-06       Impact factor: 4.553

4.  Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors.

Authors:  Giorgia Nardo; Jessica Carlet; Ludovica Marra; Laura Bonanno; Alice Boscolo; Alessandro Dal Maso; Andrea Boscolo Bragadin; Stefano Indraccolo; Elisabetta Zulato
Journal:  Front Oncol       Date:  2021-01-15       Impact factor: 6.244

5.  Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors.

Authors:  Erica L Carpenter; Despina Kontos; Bardia Yousefi; Michael J LaRiviere; Eric A Cohen; Thomas H Buckingham; Stephanie S Yee; Taylor A Black; Austin L Chien; Peter Noël; Wei-Ting Hwang; Sharyn I Katz; Charu Aggarwal; Jeffrey C Thompson
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

6.  First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer.

Authors:  Allen Chung-Cheng Huang; Chi-Hsien Huang; Jia-Shiuan Ju; Tzu-Hsuan Chiu; Pi-Hung Tung; Chin-Chou Wang; Chien-Ying Liu; Fu-Tsai Chung; Yueh-Fu Fang; Yi-Ke Guo; Chih-Hsi Scott Kuo; Cheng-Ta Yang
Journal:  Ther Adv Med Oncol       Date:  2021-07-31       Impact factor: 8.168

7.  The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study.

Authors:  Yuxiang Ma; Shuang Xin; Qingguang Lin; Wei Zhuang; Yuanyuan Zhao; Xia Zhu; Hongyun Zhao; Min Huang; Xu Xun; Yunpeng Yang; Wenfeng Fang; Li Zhang; Xueding Wang
Journal:  Ann Transl Med       Date:  2019-12

8.  Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.

Authors:  Qianqian Wang; Wen Gao; Fangyan Gao; Shidai Jin; Tianyu Qu; Fan Lin; Chen Zhang; Jingya Zhang; Zhihong Zhang; Liang Chen; Renhua Guo
Journal:  BMC Cancer       Date:  2021-05-25       Impact factor: 4.430

9.  Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.

Authors:  Yujun Zhang; Liwen Xiong; Fangfang Xie; Xiaoxuan Zheng; Ying Li; Lei Zhu; Jiayuan Sun
Journal:  Cancer Med       Date:  2021-06-25       Impact factor: 4.452

10.  Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer.

Authors:  Yiming Zhao; Shuyuan Wang; Zhengyu Yang; Yu Dong; Yanan Wang; Lele Zhang; Hai Hu; Baohui Han
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.